Transgenic and Knock-Out Services - Publications

Lionel Feigenbaum, Ph.D.

Bhandoola A, Bosselut R, Yu Q, Cowan ML, Feigenbaum L, Love PE, Singer A. CD5-mediated inhibition of TCR signaling during intrathymic selection and development does not require the CD5 extracellular domain. Eur J Immunol. 2002 Jun:32(6):1811-7.

Bodor J, Feigenbaum L, Bodorova J, Bare C, Reitz MS Jr, Gress RE. Suppression of T-cell responsiveness by inducible cAMP early repressor (ICER). J Leukoc Biol 69(6):1053-59, June 2001.

Bosselut R, Feigenbaum L, Sharrow SO, Singer A. Strength of signaling by CD4 and CD8 co-receptor tails determines the number, not the lineage direction of positively selected thymocytes. Immunity 14(4):483-94, April 2001.

Bosselut R, Kubo S, Guiner T, Kopacz JL, Altman JD, Feigenbaum L, Singer A. Role of CD8- domains in CD co-receptor function: Importance for MHC signaling, and positive selection of CD8+ T cells in the thymus. Immunity 12(4):409-18, April 2000.

Cheung C, Akiyama TE, Ward JM, Nicol CJ, Feigenbaum L, Vinson C, Gonzalez FJ.Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res. 2004 Jun 1;64(11):3849-54

Chiang YJ, Hemann MT, Hathcock KS, Tessarollo L, Feigenbaum L, Hahn WC, Hodes RJ. Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Mol Cell Biol. 2004 Aug;24(16):7024-31

Coon DW, Williams MP, Moore RJ, Edgerly ES, Steinbach CM, Roth SP, Phillips CL, Nguyen H, Dowling GA, Dunning EA, Feigenbaum LZ. The Northern California Chronic Care Network for Dementia. J Am Geriatr Soc. 2004 Jan;52(1):150-6

Corchero J, Granvil C, Hayhurst G, Pimprale S, Feigenbaum L, Idle J, and Gonzalez F: The CYP2D6 humanized mouse: Effect of the human CYP2D6 transgene and HNF4a on the disposition of debrisoquine in the mouse. Mol Pharmacol.2001 Dec;60(6):1260-7

Erman B, Feigenbaum L, Coligan JE, Singer A. Early TCRalpha expression generates TCRalphagamma complexes that signal the DN-to-DP transition and impair development. Nat Immunol. 2002 Jun;3(6):564-9

Felix K, Polack A, Pretsch W, Jackson SH, Feigenbaum L, Bornkamm GW, Janz S. Moderate hypermutability of a transgenic lacZ reporter gene in Myc-dependent inflammation-induced plasma cell tumors in mice. Cancer Res. 2004 Jan 15;64(2):530-7.

Granvil CP, Yu AM, Elizondo G, Akiyama TE, Cheung C, Feigenbaum L, Krausz KW, Gonzalez FJ. Expression of the Human CYP3A4 Gene in the Small Intestine of Transgenic Mice: In Vitro Metabolism and Pharmacokinetics of Midazolam. Drug Metab Dispos. 2003 May:31 (5): 548-58.

Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, Parks SS, Gerbitz A, Klobeck G, Hoertnagel K, Polack A, Bornkamm GW, Janz S, Morse HC III. Burkitt lymphoma in the mouse. J Exp Med 192(8):1183-90, October 16, 2001.

Kusakabe T, Kawaguchi A, Kawaguchi R, Feigenbaum L, Kimura S. Thyrocyte-specific expression of Cre recombinase in transgenic mice. Genesis. 2004 Jul;39(3):212-6

Liu X, Adams A., Wildt KF, Aronow B, Feigenbaum L, Bosselut R. Restricting Zap70 expression to CD4+CD8+ thymocytes reveals a T cell receptor-dependent proofreading mechanism controlling the completion of positive selection. J Exp Med. 2003 Feb3;197(3):363-73.

Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, Waldmann TA, Tagaya Y. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci USA 97(21):11445-50, October 10, 2000.

Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, Feigenbaum L, Lee E, Aoyama T, Eckhaus M, Reitman ML, Vinson C. Life without white fat: A transgenic mouse. Genes Dev 12(20):3168 -81, 1998.

Moustafa ME, Carlson BA, El-Saadani MA, Kryukov GV, Sun QA, Harney JW, Hill KE, Combs GF, Feigenbaum L, Mansur DB, Burk RF, Berry MJ, Diamond AM, Lee BJ, Gladyshev VN, Hatfield DL. Selective inhibition of selenocystein tRNA maturation and selenoprotein synthesis in transgenic mice expressing isopentenyladenosine-deficient selenocystein tRNA. Mol Cell Biol 21(11):3840-52, June 2001

Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003 Aug 18;198(4):569-80

Yu Z, Theoret MR, Touloukian CE, Surman DR, Garman SC, Feigenbaum L, Baxter TK, Baker BM, Restifo NP. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest. 2004 Aug;114(4):551-9

Xu Fang Pei, Ph.D.

Pei XF. The human papillomavirus E6/E7 genes induce discoordinate changes in the expression of cell growth regulatory proteins. Carcinogenesis 17:1395-1401, 1996.

Pei XF, Qin NG, Meck JM, Schlegel R. Keratinocytes immortalized by HPV DNA exhibit alterations dependent upon host genetic background and transfected viral genes. Pathobiology 62:43-52, 1994.

Pei, XF, Sherman L, Sun YH, Schlegel R. HPV-16 E7 protein bypasses keratinocyte growth inhibition by serum and calcium. Carcinogenesis 19:1481-91, 1998.

Shnitman S, Jackman A, Pei XF, Schlegel R, Sherman L. Induction of P53 independent apoptosis in human immortalized keratinocytes (HaCaT) by UV/C irradiation and inhibition by human papillomavirus E6 and #7 oncoproteins. Int J Cancer 75:96-104, 1998.

Steinmann K, Pei XF, Schlegel R, Schlegel R. Elevated expression and activity of mitotic regulatory proteins in human papillomavirus-immortalized keratinocytes. Oncogene 9:397-94, 1994.